revvity-illum1920x640
Whitepaper

Preclinical screening platforms for Antibody-Drug Conjugate therapeutics

Antibody Drug Conjugates (ADCs) are among the most rapidly expanding oncology therapeutic categories, with hundreds of candidates undergoing active clinical development.

In this white paper, you will learn how systematically evaluating antibody-drug conjugate (ADC) therapeutics through in vitro screening across diverse cell lines is essential for improving therapeutic efficacy and reducing off-target effects.

In this white paper, you will learn:

  • The importance of cell model generation for ADCs
  • How cell panel screening is being used to advance ADC-based therapies
  • The role of screening for genetic drivers and mechanisms of action and resistance
  • Why to use immune cell-based screening to improve ADC structure

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Preclinical screening platforms for Antibody-Drug Conjugate therapeutics

Download Whitepaper